Comparable fitness and transmissibility between oseltamivirresistant pandemic 2009 and seasonal H1N1 influenza viruses with the H275Y neuraminidase mutation

Journal of Virology

Volumn 86, Issue 19, 2012, Pages 10558-10570

  Wong, Diana D Y ^a   Choy, Ka Tim ^a   Chan, Renee W Y ^a   Sia, Sin Fun ^a   Chiu, Hsin Ping ^a   Cheung, Peter P H ^a   Chan, Michael C W ^a   Peiris, J S Malik ^a,b   Yen, Hui Ling ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b HKU PASTEUR RESEARCH CENTRE   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

3' SIALYLACTOSE; 6' SIALYLACTOSE; LACTOSE; MUCIN; OSELTAMIVIR; UNCLASSIFIED DRUG; VIRUS HEMAGGLUTININ; VIRUS SIALIDASE;

2009 H1N1 INFLUENZA; AIRWAY; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME KINETICS; EPITHELIUM CELL; GENE FUNCTION; GENE LOSS; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFECTION; INFLUENZA VIRUS A H1N1; NA GENE; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; SEASONAL INFLUENZA; VIROGENESIS; VIRUS GENE; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANIMALS; ANTIGENS; ANTIVIRAL AGENTS; DOGS; DRUG RESISTANCE, VIRAL; FERRETS; HEK293 CELLS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; KINETICS; MALE; MUCINS; MUTATION; NEURAMINIDASE; OSELTAMIVIR; VIRUS REPLICATION;

MUSTELA; ORTHOMYXOVIRIDAE;

EID: 84869067378     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00985-12     Document Type: Article

References (73)

1. Air GM, Laver WG. 1989. The neuraminidase of influenza virus. Proteins 6:341-356.
2. Baz M, Abed Y, Simon P, Hamelin ME, Boivin G. 2010. Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses. J. Infect. Dis. 201:740-745.
3. Belshe RB, Smith MH, Hall CB, Betts R, Hay AJ. 1988. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J. Virol. 62:1508-1512.
4. Bloom JD, Gong LI, Baltimore D. 2010. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 328: 1272-1275.
5. Brookes DW, Miah S, Lackenby A, Hartgroves L, Barclay WS. 2011. Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitness. J. Antimicrob. Chemother. 66:466-470.
6. Calatayud L, et al. 2011. Oseltamivir-resistant pandemic (H1N1) 2009 virus infection in England and Scotland, 2009-2010. Emerg. Infect. Dis. 17:1807-1815.
7. CDC. 2010. Update: influenza activity-United States, 2009-10 season. Morb. Mortal. Wkly. Rep. 59:8.
8. Chan RW, et al. 2010. Influenza H5N1 and H1N1 virus replication and innate immune responses in bronchial epithelial cells are influenced by the state of differentiation. PLoS One 5:e8713. doi:10.1371/journal. pone.0008713.
9. Chen LF, et al. 2011. Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patients, North Carolina, 2009. J. Infect. Dis. 203:838-846.
10. de Jong MD, et al. 2005. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353:2667-2672.
11. Dharan NJ, et al. 2009. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 301:1034-1041.
12. Donatelli I, et al. 1991. Detection of two antigenic subpopulations of A(H1N1) influenza viruses from pigs: antigenic drift or interspecies transmission? J. Med. Virol. 34:248-257.
13. Duan S, et al. 2010. Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets. PLoS Pathog. 6:e1001022. doi:10.1371/journal.ppat.1001022.
14. Escuret V, et al. 2008. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors. J. Clin. Virol. 41:25-28.
15. Garten RJ, et al. 2009. Antigenic and genetic characteristics of swineorigin 2009 A(H1N1) influenza viruses circulating in humans. Science 325:197-201.
16. Ginting TE, et al. 2012. Amino acid changes in hemagglutinin contribute to the replication of oseltamivir-resistant H1N1 influenza viruses. J. Virol. 86:121-127.
17. Godding V, et al. 1998. Secretory component production by human bronchial epithelial cells is upregulated by interferon gamma. Eur. Respir. J. 11:1043-1052.
18. Graitcer SB, et al. 2011. Characteristics of patients with oseltamivirresistant pandemic (H1N1) 2009, United States. Emerg. Infect. Dis. 17: 255-257.
19. Gubareva LV. 2004. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res. 103:199-203.
20. Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo Y, Hayden FG. 2001. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis. 183:523-531.
21. Gubareva LV, et al. 2010. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro. Antivir. Ther. 15: 1151-1159.
22. Gubareva LV, Webster RG, Hayden FG. 2002. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antiviral Res. 53:47-61.
23. Hamelin ME, et al. 2010. Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets. PLoS Pathog. 6:e1001015. doi:10.1371/journal.ppat.1001015.
24. Hamelin ME, et al. 2011. Reduced airbourne transmission of oseltamivirresistant pandemic A/H1N1 virus in ferrets. Antivir. Ther. 16:775-779.
25. Hattrup CL, Gendler SJ. 2008. Structure and function of the cell surface (tethered) mucins. Annu. Rev. Physiol. 70:431-457.
26. Hauge SH, Dudman S, Borgen K, Lackenby A, Hungnes O. 2009. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg. Infect. Dis. 15:155-162.
27. Herlocher ML, et al. 2004. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J. Infect. Dis. 190:1627-1630.
28. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. 2000. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc. Natl. Acad. Sci. U. S. A. 97:6108-6113.
29. Holmen JM, et al. 2004. Mucins and their O-glycans from human bronchial epithelial cell cultures. Am. J. Physiol. Lung Cell Mol. Physiol. 287: L824-L834.
30. Hurt AC, et al. 2011. Oseltamivir-resistant influenza viruses circulating during the first year of the influenza A(H1N1) 2009 pandemic in the Asia-Pacific region, March 2009 to March 2010. Euro Surveill. 16:19770.
31. Hurt AC, et al. 2009. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res. 83:90-93.
32. Hurt AC, et al. 2011. Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza. N. Engl. J. Med. 365:2541-2542.
33. Hurt AC, et al. 2010. Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model. J. Virol. 84:9427-9438.
34. Ilyushina NA, et al. 2010. Adaptation of pandemic H1N1 influenza viruses in mice. J. Virol. 84:8607-8616.
35. Ives JAL, et al. 2002. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res. 55: 307-317.
36. Kesimer M, et al. 2009. Tracheobronchial air-liquid interface cell culture: a model for innate mucosal defense of the upper airways? Am. J. Physiol. Lung Cell Mol. Physiol. 296:L92-L100.
37. Kiso M, et al. 2010. Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A viruses. PLoS Pathog. 6:e1001079. doi:10.1371/journal.ppat.1001079.
38. Kobasa D, et al. 1999. Amino acid residues contributing to the substrate specificity of the influenza A virus neuraminidase. J. Virol. 73:6743-6751.
39. Kryazhimskiy S, Dushoff J, Bazykin GA, Plotkin JB. 2011. Prevalence of epistasis in the evolution of influenza A surface proteins. PLoS Genet. 7:e1001301. doi:10.1371/journal.pgen.1001301.
40. Lackenby A, et al. 2008. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill. 13:8026.
41. Le QM, et al. 2005. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437:1108.
42. Le QM, et al. 2010. A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. N. Engl. J. Med. 362:86-87.
43. Matrosovich M, Matrosovich T, Carr J, Roberts NA, Klenk H-D. 2003. Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J. Virol. 77:8418-8425.
44. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. 2004. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J. Virol. 78:12665-12667.
45. McKimm-Breschkin JL. 2000. Resistance of influenza viruses to neuraminidase inhibitors: a review. Antiviral Res. 47:1-17.
46. Meijer A, et al. 2011. Oseltamivir-resistant pandemic A(H1N1) 2009 influenza viruses detected through enhanced surveillance in the Netherlands, 2009-2010. Antiviral Res. 92:81-89.
47. Meijer A, et al. 2009. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg. Infect. Dis. 15:552-560.
48. Memoli MJ, et al. 2011. Multidrug-resistant 2009 pandemic influenza A(H1N1) viruses maintain fitness and transmissibility in ferrets. J. Infect. Dis. 203:348-357.
49. Monto AS, et al. 2006. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob. Agents Chemother. 50:2395-2402.
50. Moore C, et al. 2011. Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus in a hematology unit. J. Infect. Dis. 203:18-24.
51. Nguyen JT, et al. 2010. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 5:e9332. doi:10.1371/journal.pone.0009332.
52. Pizzorno A, Bouhy X, Abed Y, Boivin G. 2011. Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. J. Infect. Dis. 203:25-31.
53. Potier M, Mameli L, Belisle M, Dallaire L, Melancon SB. 1979. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferylalpha-D-N-acetylneuraminate) substrate. Anal. Biochem. 94:287-296.
54. Rameix-Welti MA, Enouf V, Cuvelier F, Jeannin P, van der Werf S. 2008. Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. PLoS Pathog. 4:e1000103. doi:10.1371/journal.ppat.e1000103.
55. Rameix-Welti MA, et al. 2011. Neuraminidase of 2007-2008 influenza A(H1N1) viruses shows increased affinity for sialic acids due to the D344N substitution. Antivir. Ther. 16:597-603.
56. Reddy D. 2010. Responding to pandemic (H1N1) 2009 influenza: the role of oseltamivir. J. Antimicrob. Chemother. 65(Suppl 2):ii35-ii40.
57. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. (Lond.) 27:493-497.
58. Sandbulte MR, et al. 2011. Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses. Proc. Natl. Acad. Sci. U. S. A. 108:20748-20753.
59. Scholtissek C, Burger H, Bachmann PA, Hannoun C. 1983. Genetic relatedness of hemagglutinins of the H1 subtype of influenza A viruses isolated from swine and birds. Virology 129:521-523.
60. Seibert CW, et al. 2010. Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models. J. Virol. 84:11219-11226.
61. Sheu TG, et al. 2008. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob. Agents Chemother. 52:3284-3292.
62. Smith GJ, et al. 2009. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 459:1122-1125.
63. Storms AD, et al. 2012. Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010-11. Emerg. Infect. Dis. 18:308-311.
64. Tashiro M, et al. 2009. Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996-2007. Antivir. Ther. 14:751-761.
65. Thornton DJ, Rousseau K, McGuckin MA. 2008. Structure and function of the polymeric mucins in airways mucus. Annu. Rev. Physiol. 70:459-486.
66. von Itzstein M, et al. 1993. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363:418-423.
67. WHO. 2009. Influenza A(H1N1) virus resistance to oseltamivir, 2008/2009 influenza season, Northern Hemisphere. WHO, Geneva, Switzerland.
68. WHO. 2010. Update on oseltamivir-resistant pandemic A (H1N1) 2009 influenza virus: January 2010. Wkly. Epidemiol. Rec. 85:37-40.
69. Wu WL, et al. 2012. The 2008-2009 H1N1 influenza virus exhibits reduced susceptibility to antibody inhibition: implications for the prevalence of oseltamivir resistant variant viruses. Antiviral Res. 93: 144-153.
70. Ye J, et al. 2010. Variations in the hemagglutinin of the 2009 H1N1 pandemic virus: potential for strains with altered virulence phenotype? PLoS Pathog. 6:e1001145. doi:10.1371/journal.ppat.1001145.
71. Yen HL, et al. 2005. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob. Agents Chemother. 49:4075-4084.
72. Yen HL, et al. 2006. Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. J. Virol. 80: 8787-8795.
73. Yen HL, et al. 2007. Inefficient transmission of H5N1 influenza viruses in a ferret contact model. J. Virol. 81:6890-6898.